• news.cision.com/
  • IDL Biotech/
  • New interesting findings for the tumor marker UBC® Rapid Result from a new German multicenter study
English

New interesting findings for the tumor marker UBC® Rapid Result from a new German multicenter study

Report this content

Stockholm, 21.3.2016

At this year’s EAU (European Association of Urology) meeting in Munich, March 11-15, a German multi-center study on UBC® Rapid was presented. Responsible for the study was Dr Thorsten Ecke, Helios Hospital, Department of Urology, Bad Sarrow. Urine samples were analyzed by UBC® Rapid POC test and evaluated quantitatively. The study showed very high sensitivity and specificity for high grade tumors generally 71/94%, and for CIS patients the sensitivity was even higher 87%.The authors concluded that UBC® Rapid should be added in the diagnostics for high risk bladder cancer and in particular for CIS patients with tumors in the bladder.

For further information, please contact: 

Lars Skoglund 
Vice President Sales & Marketing

IDL Biotech AB (publ)
+46 8 799 67 50

IDL Biotech AB (publ) is a public Swedish Biotech company, specialized in the field of in vitro diagnostics within Oncology and Bacteriology. The company develops, manufacture and market high quality in vitro diagnostic products enabling reliable diagnosis for efficient patient management in conditions of high clinical concern. IDL’s products are distributed mainly in Europe and Asia. IDL Biotech is listed on the Swedish equities market place, Aktietorget. 

Documents & Links